Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | TFPI | P10646 | 1/20 | 0.49 |
| ▸ | IL23R | Q5VWK5 | 6/20 | 0.47 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.46 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974829 | 1.00 | F2 (0.52) | F2TFPIIL23RNTSR2NTSR1 | |
| SCHEMBL29353517 | 0.93 | TFPI (0.57) | F2TFPIIL23R | |
| SCHEMBL29974987 | 0.91 | NTSR2 (0.54) | F2NTSR2NTSR1KISS1R | |
| SCHEMBL29974534 | 0.91 | NTSR2 (0.54) | F2NTSR2NTSR1KISS1R | |
| SCHEMBL29611881 | 0.90 | F2 (0.59) | F2TFPIIL23RNTSR2NTSR1 | |
| SCHEMBL8893062 | 0.89 | IL23R (0.57) | TFPIIL23RKISS1RPSEN1PSEN2 | |
| SCHEMBL8894047 | 0.89 | VIPR2 (0.52) | F2IL23RKISS1RBACE1BACE2 | |
| SCHEMBL29611494 | 0.87 | BACE1 (0.58) | F2TFPIIL23RBACE1BACE2 | |
| SCHEMBL29975231 | 0.87 | ACE (0.53) | BACE1BACE2MAGI3 | |
| SCHEMBL29438956 | 0.87 | F2 (0.55) | F2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116984-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | NATIONAL SCIENCE FOUNDATION | 2024-04-11 | — | — | US | disclosed |
| EP-4329791-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | University of Notre Dame du Lac (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230399361-A1 | MACROCYCLIC PEPTIDES | UNIVERSITY OF NOTRE DAME DU LAC | 2023-12-14 | — | — | US | disclosed |
| WO-2023129899-A2 | BIOMARKERS AND THERAPEUTIC TARGETS FOR NEURODEGENERATIVE DISEASES INVOLVING K311-ACETYLATED TAU | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2022232007-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116984-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | PRNP, MAPT, APP | F2 3097/4885TFPI 1981/4885IL23R 3151/4885 |
| US-20230399361-A1 | MACROCYCLIC PEPTIDES | APP, MAPT, NEFM | F2 1594/4885TFPI 472/4885IL23R 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.